Bioequivalence (BE)

Bioequivalence is the scientific and regulatory determination that two pharmaceutical formulations — typically a generic and a reference (innovator) product — deliver the same active substance to the site of action at the same rate and extent under equivalent conditions.

Regulatory agencies use bioequivalence as the principal standard for approving generic medicines without requiring full clinical efficacy trials to be repeated. The underlying rationale is that if two formulations produce statistically comparable plasma concentration–time profiles, their clinical outcomes can reasonably be assumed equivalent. In Australia, the Therapeutic Goods Administration (TGA) sets out the accepted methodology in its Guideline on the Investigation of Bioequivalence, which aligns broadly with European Medicines Agency (EMA) and WHO guidance.

The standard pharmacokinetic parameters assessed are the area under the concentration–time curve (AUC), which reflects total drug exposure, and the peak plasma concentration (Cmax). A generic product is typically accepted as bioequivalent when the 90% confidence interval for the ratio of these parameters falls within 80–125% of the reference product's values , a range established by convention to represent a clinically acceptable margin of difference.

Bioequivalence studies are conducted in healthy adult volunteers under controlled fasting or fed conditions, depending on the product's labelling. For medicines with narrow therapeutic indices , that is, those where small differences in plasma levels carry meaningful clinical consequences , regulators may apply tighter acceptance criteria or require additional study designs. The TGA's Australian Register of Therapeutic Goods (ARTG) entry for a generic product lists the reference product against which bioequivalence was demonstrated.

Bioequivalence is distinct from pharmaceutical equivalence (same active ingredient, dose form, and strength) and therapeutic equivalence (demonstrated to produce the same clinical effect and safety profile in patients). A product may be pharmaceutically equivalent without being bioequivalent if, for example, differences in excipients, particle size, or manufacturing process alter the rate of absorption. These distinctions are defined in the TGA's Access to Unapproved Therapeutic Goods guidance and in the Poisons Standard (the current Therapeutic Goods Order No. 92) where scheduling intersects with substitution rules.

Sources: